

The cAMP-Regulated Pathways Seen in Apicomplexan Parasites for Drug Development

Alessandra Salmona*

Department of Food and Drug, University of Parma, Parco Area Delle Scienze 27/A, 43124 Parma, Italy

DESCRIPTION

One of the most significant tropical diseases affecting humans is malaria, which is brought on by several *Plasmodium* species, which are protozoan parasites from the apicomplexa. The *Plasmodium*, *Toxoplasma*, and *Cryptosporidium* genera of apicomplexan parasites, which can cause malaria, toxoplasmosis, and cryptosporidiosis, have a plastid-like structure called the “apicoplast” [1]. Despite of enormous efforts and advancements in drug development, there are still few medications available for the treatment of these neglected diseases, largely because of developing drug resistance to commercially available medications. It's essential to have a productive centre focused on finding new routes that contain new therapeutic targets. The distinct cAMP-regulated pathways seen in apicomplexan parasites are unique makes them an attractive resource for the development of new drugs. Here, with a particular emphasis on *Plasmodium*, the most significant distinctions from the human host are outlined.

Plasmodium lacks G-proteins and GPCRs in its non-canonical cAMP-regulated pathway

Plasmodium, the deadly parasite that causes malaria, is the most significant member of the apicomplexa. The malaria parasite must grow in two distinct settings after infecting the human host, namely the preerythrocytic stage in the liver and the erythrocytic blood stages. After that, the mosquito enters a sexual stage, which causes the growth of ookinetes in its midgut to create an oocyst that produces sporozoites in the salivary glands [2]. Only signalling processes can enable the parasite to quickly respond to these developmental changes. The dearth of available genome data has prevented research on apicomplexan parasites from progressing as quickly as that on cyclic nucleotide controlled pathways in humans. However, new genome sequencing discoveries have shown that the components of their cyclic nucleotide pathways differ.

Toxoplasma gondii is dependent on GPCR-mediated signalling from the infected human host cell

The common protozoan parasite *Toxoplasma gondii* is the cause of toxoplasmosis [3]. 30% of people are affected by it. The oocyste, tachyzoite, and bradyzoite are the three developmental forms that it takes on throughout its life cycle. Feces from cats, where the oocysts are found, are the means of transmission. Congenital toxoplasmosis, caused by the rapidly replicating tachyzoite form of the parasite, causes tissue damage and foetal infection in pregnant women. Tachyzoites can transform into bradyzoites in particular in muscles and the Central Nervous System (CNS) depending on the immunological response of the human host. Some tachyzoites, however, have the ability to evade the host's immunological reaction and transform back into bradyzoites. Bradyzoites can be consumed in meat and transform into tachyzoites when they are swallowed by a human host.

Cryptosporidium, a non-intracellular parasite, reproducing without canonical G-proteins and GPCRs

Both *Cryptosporidium hominis* and *Cryptosporidium parvum*, which can infect both humans and animals, produce human cryptosporidiosis, a self-limiting diarrhoea in healthy individuals. The condition can progress into severe diarrhoea with effects on the biliary tree and the respiratory organs in immunocompromised individuals, such as HIV-1 infected individuals or young children [4]. The life cycle begins with the expulsion of sporulated oocysts through the respiratory system or in the faeces. Sporozoites are secreted after intake or inhalation and parasitize epithelial cells. After then, asexual reproduction (schizogony or merogony) begins before the sexually mature micro- and macrogamonts form the oocyste.

CONCLUSIONS

The discovery of pathways with novel targets is crucial for the control and eradication of major worldwide parasite diseases at a

Correspondence to: Alessandra Salmona, Department of Food and Drug, University of Parma, Parco Area Delle Scienze 27/A, 43124 Parma, Italy, E-mail: alessandra.salmona@unipr.it

Received: 21-Jul-2022, Manuscript No. JCS-22-19304; **Editor assigned:** 26-Jul-2022, PreQC No. JCS-22-19304 (PQ); **Reviewed:** 09-Aug-2022, QC No. JCS-22-19304; **Revised:** 16-Aug-2022, Manuscript No. JCS-22-19304 (R); **Published:** 23-Aug-2022, DOI: 10.35248/2576-1471.22.07.300

Citation: Salmona A (2022) The cAMP-Regulated Pathways Seen in Apicomplexan Parasites for Drug Development. J Cell Signal. 7:300

Copyright: © 2022 Salmona A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

time when traditional treatment is becoming less effective. The non-canonical cAMP-regulated pathways of apicomplexan parasites that cause toxoplasmosis, cryptosporidiosis, and malaria offer a useful tool in this situation. This discussion demonstrates various approaches to solving the issue.

- Inhibition of the host proteins may lessen parasite load because canonical G-proteins and GPCRs are missing in these parasites but present in the mammalian host. The canonical, cAMP-regulated pathways of the human host are very important for the survival of all three genera of apicomplexan parasites.
- An appealing strategy to stop the parasite's invasion and egress is to inhibit the Rap1 protein in the guanine nucleotide exchange pathway.
- Kinase G is the most promising target in *Plasmodium* out of the secondary effector proteins, or the family of ACG kinases, because it performs crucial regulatory roles throughout the whole parasite life cycle. The WHO's criteria that a single treatment eliminates the parasite in each embryonic stage is already met by an inhibitor with an imidazopyridine lead structure.

- Small Ras GTPases in all three genera, which interact with certain host enzymes to speed up parasite invasion and proliferation, have not yet been fully utilized in drug discovery.

REFERENCES

1. Millholland MG, Mishra S, Dupont CD, Love MS, Patel B, Shilling D, et al. A host GPCR signaling network required for the cytolysis of infected cells facilitates release of apicomplexan parasites. *Cell Host & Microbe*. 2013;13(1): 15-28.
2. Zheng W, Liu F, He Y, Liu Q, Humphreys GB, Tsuboi T, et al. Functional characterization of *Plasmodium berghei* PSOP25 during ookinete development and as a malaria transmission-blocking vaccine candidate. *Parasites & Vectors*. 2017;10(1): 188-196.
3. Kremer K, Kamin D, Rittweger E, Wilkes J, Flammer H, Mahler S, et al. An overexpression screen of *Toxoplasma gondii* Rab-GTPases reveals distinct transport routes to the micronemes. *PLoS Pathogens*. 2013;9(3): 94-98.
4. Leitch GJ, He Q. Cryptosporidiosis-an overview. *Journal of Biomedical Research*. 2011;25(1): 1-6.